American Oncology Network Inc (AONC): Market Cap to Revenue

Symbol and logo of brand AON (AONC)

Amid growing demand for private oncology center support and AI-driven digitalization of records, American Oncology Network is facing inflationary pressure on the cost of imported equipment. The current P/S ratio confirms the impact of these costs on share prices, where 0.00 serves as the base parameter value. This chart clearly demonstrates the market reaction to fundamental shifts in the company's operating expenses.

AONC American Oncology Network Inc Price-to-Revenue Ratio (03/30/2024 - 08/04/2024)

Analytical breakdowns for American Oncology Network Inc (AONC)

- stock value and consensus price forecast:
- stock exchange capitalization data:
General company analysis:AONC American Oncology Network
Core merchandise of American Oncology Network, Inc.

American Oncology Network (AONC) is scaling its B2B platform for the consolidation of regional US oncology clinics, aiming for dominance in the specialized treatment market. By analyzing the current P/S ratio, an investor assesses market capitalization relative to revenue, which, amid inflation, confirms the business's ability to pass costs onto consumers and determines the real resilience of the share price.

Competitors of American Oncology Network

ONC - Price to Sales|P/S Multiple HALO (Halozyme Therapeutics, Inc.)|Revolution Medicines (RVMD) - Price to Sales|ascentage.com - P/S Multiple|Market Capitalization-to-Revenue Ratio CGON (cgoncology.com)|URGN: P/S Multiple|Bicara Therapeutics Inc (BCAX) - P/S Multiple|Price-to-Revenue Ratio personalis.com|Market Cap to Revenue Erasca Corp (ERAS)|Market Cap to Revenue DCTH (Delcath)|Price-to-Revenue Coefficient Y-mAbs Therapeutics, Inc.|P/S Multiple AURA (Aura Biosciences Inc)|Market Capitalization-to-Revenue Ratio CADL|ARAY: Market Cap to Revenue|Price-to-Revenue Coefficient sellaslifesciences.com SLS|ACTU (Actuate Therapeutics, Inc) - Market Cap to Revenue|Market Cap to Revenue Ratio CTOR|Price-to-Revenue Ratio TuHURA Biosciences Inc.|TARA: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Fate Therapeutics (FATE)|Price-to-Revenue Coefficient Aadi Bioscience|Price-to-Revenue Ratio TScan Therapeutics Inc TCRX|CSBR: Market Cap to Revenue Ratio|XBIT: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio CVM (cel-sci.com)|OSTX: P/S Multiple|Price to Sales Radiopharm Theranostics Ltd (RADX)|ARTV (Artiva) - P/S Multiple|Market Cap to Revenue Ratio ANL (Adlai Nortye)|Price-to-Revenue Ratio Veru Pharma (VERU)|P/S Multiple Tempest Tx (TPST)|Price-to-Revenue Ratio xiliotx.com XLO|Enochian BioSciences - Price-to-Revenue Ratio|Mural Oncology - P/S Multiple|KAPA - P/S Multiple|OnKure Therapeutics Inc (OKUR) - Price-to-Revenue Ratio|Market Cap to Revenue CytoMed|Price-to-Revenue Ratio curis.com|Market Cap to Revenue Apollomics, Inc. (APLM)|P/S Multiple THAR|Advanced Biomed Corp - Market Cap to Revenue Ratio|Price-to-Revenue Ratio Genprex GNPX|Price-to-Revenue Coefficient Calidi Bio (CLDI)|sunshinebiopharma.com - P/S Multiple|Price to Sales xeneticbio.com|salariuspharma.com (SLRX) - Price-to-Revenue Ratio|Purple Biotech Ltd. - Market Capitalization-to-Revenue Ratio|Market Cap to Revenue BGNE|P/S Multiple Checkpoint Therapeutics Inc.|P/S Multiple ELEV|Market Cap to Revenue iCAD ICAD|P/S Multiple IKNA (Ikena Oncology, Inc.)|Market Capitalization-to-Revenue Ratio NTBL|Viracta Therapeutics, Inc. - P/S Multiple|Market Capitalization-to-Revenue Ratio MOR (MorphoSys Inc)|NAYA (NAYA Biosciences Inc) - Market Cap to Revenue|Market Cap to Revenue Ascentage Pharma Group Ltd